We recently participated in an interesting biomarkers discussion Webinar presented by Defined Health, a business development strategy consulting firm catering for pharmaceutical, biotech and healthcare investment industries. The theme of the webinar posed the question whether Pharma can survive (or thrive) in the current challenging climate of higher R&D costs, increased late stage attrition and [...] Read more »